Expressions of MACC1 and c-Met Proteins in Lung Adenocarcinoma and Their Correlation with Postoperative Recurrence
-
摘要:目的
检测MACC1、c-Met蛋白在肺腺癌组织中的表达，及其在患者术后复发中的预测价值。
方法收集完全性切除的肺腺癌患者术后病理标本102例和癌旁组织57例，采用免疫组织化学技术检测MACC1和c-Met蛋白在肺腺癌和癌旁组织中的表达，对患者行定期随访，分析MACC1和c-Met蛋白的表达与患者术后复发的关系。
结果MACC1和c-Met在癌组织中的阳性表达率分别为59.80%、54.90%，明显高于癌旁组织中的7.01%、10.53%，差异有统计学意义（P＜0.05）。MACC1、c-Met蛋白的表达与性别年龄无关，与肿瘤T分期、淋巴结转移、病理TNM分期有关（P＜0.05）。MACC1与c-Met的表达之间呈正相关（r=0.262, P=0.008）。MACC1阳性组2年内复发率为73.77%，明显高于阴性组的31.71%（χ2=17.686, P＜0.001）。c-Met阳性组2年内复发率为76.79%，高于阴性组的34.78%（χ2=18.272, P＜0.001）。Cox回归多因素提示MACC1和c-Met蛋白的表达、术后病理分期、肿瘤T分期及淋巴结转移情况是腺癌患者复发转移的危险因素。
结论MACC1和c-Met蛋白在肺腺癌组织中表达与肿瘤T分期、淋巴结转移、病理分期有关，影响肺腺癌患者术后无瘤生存期，是复发转移的危险因素。
-
关键词:
- 结肠癌转移相关基因1 /
- c-Met /
- 肺腺癌 /
- 复发
Abstract:ObjectiveTo detect the expressions of metastasis associated in colon cancer 1(MACC1) and c-Met proteins in patients with lung adenocarcinoma and analyze the suitability of these protein expressions to predict postoperative recurrence.
MethodsThere were 102 lung adenocarcinoma patients who underwent a completely surgical excision from July 2011 to July 2013. The expression of MACC1 and c-Met proteins in lung adenocarcinoma tissues and normal lung tissues were detected by immunohistochemistry. We had the regular follow-up for all patients. The correlation between protein expressions and postoperative recurrence was analyzed.
ResultsIn 102 cases of lung adenocarcinoma tissues and 57 cases of normal lung tissues, the positive MACC1 protein expression rate was higher in tumor tissues than in normal lung tissues(59.80% vs. 7.01%, P<0.05). The positive c-Met protein expression rate was higher in tumor tissues than in normal tissues (54.90% vs. 10.53% , P<0.05). The gender and age were not found to be correlated with MACC1 or c-Met protein expressions, while significant association were shown between the expressions of MACC1, c-Met proteins and pathological T stage, lymph node metastasis, TNM stage(P<0.05). The MACC1 and c-Met protein expressions were positively correlated(r=0.262, P=0.008). The relapse rate within two years with MACC1 positive expression was 73.77% and higher than 31.71% with negative expression(χ2=17.686, P<0.001). There were different 2-year relapse rates between positive and negative expressions of c-Met protein(76.79% vs. 34.78%, χ2=18.272, P<0.001). Cox regression analysis showed that MACC1 expression, c-Met expression, postoperative pathological stage, T stage and lymph node metastasis were the prognostic factors of the recurrence and metastasis of lung adenocarcinoma.
ConclusionThe expression levels of MACC1 and c-Met protein are associated with T stage, lymph node metastasis and pathological stage, and are the prognostic factors of the recurrence and metastasis of lung adenocarcinoma.
-
Key words:
- Metastasis associated in colon cancer1(MACC1) /
- c-Met /
- Lung adenocarcinoma /
- Recurrence
-
-
![]()
图 2 c-Met（A）和MACC1（B）蛋白阳性表达与阴性表达患者的无病生存期曲线
Figure 2 Disease-free survival curves of patients with positive and negative c-Met(A) and MACC1(B) expression
表 1 c-Met和MACC1蛋白表达与肺腺癌患者临床及病理特点的关系
Table 1 Clinical and pathological characteristics of lung adenocarcinoma patients with c-Met and MACC1 overexpression
下载: 导出CSV
表 2 Cox多因素分析肺腺癌患者复发的危险因素
Table 2 Cox multivariate analysis of risk factors for patients with lung adenocarcinoma recurrence
下载: 导出CSV
-
[1] 李学祥, 王慜杰, 高佳, 等. 肺肿瘤患者临床病理特征回顾性分析[J].中华肿瘤防治杂志, 2012, 19(2): 130-3. http://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201202015.htm Li XX, Wang MJ, Gao J, et al. Retrospective analysis of clinical pathology characteristic in patients with lung neoplasms[J].Zhonghua Zhong Liu Fang Zhi Za Zhi, 2012, 19(2): 130-3. http://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201202015.htm
[1] Li XX, Wang MJ, Gao J, et al. Retrospective analysis of clinical pathology characteristic in patients with lung neoplasms[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2012, 19(2): 130-3. [李学 祥, 王慜杰, 高佳, 等. 肺肿瘤患者临床病理特征回顾性分析[J]. 中华肿瘤防治杂志, 2012, 19(2): 130-3.] [2] Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan:a Japanese lung cancer registry study[J]. Lung Cancer, 2005, 50(2): 227-34. doi: 10.1016/j.lungcan.2005.05.021
[2] Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan:a Japanese lung cancer registry study[J]. Lung Cancer, 2005, 50(2): 227-34. [3] Stein U. MACC1-a novel target for solid cancers[J]. Expert Opin Ther Targets, 2013, 17(9): 1039-52. http://cn.bing.com/academic/profile?id=2083029824&encoded=0&v=paper_preview&mkt=zh-cn
[3] Stein U. MACC1-a novel target for solid cancers[J]. Expert Opin Ther Targets, 2013, 17(9): 1039-52. [4] Gumustekin M, Kargi A, Bulut G, et al. HGF/c-Met overexpression, but not met mution, correlates with progression of non-small cell lung cancer[J]. Pathol Oncol Res, 2012, 18(2): 209-18. [4] Gumustekin M, Kargi A, Bulut G, et al. HGF/c-Met overexpression, but not met mution, correlates with progression of non-small cell lung cancer[J]. Pathol Oncol Res, 2012, 18(2): 209-18. doi: 10.1007/s12253-011-9430-7
[5] Qiu J, Huang P, Liu Q, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma[J]. J Transl Med, 2011, 9: 166. doi: 10.1186/1479-5876-9-166
[5] Qiu J, Huang P, Liu Q, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma[J]. J Transl Med, 20 11, 9: 166. [6] Fan X, Zhang X, Wang H, et al. Reevaluation of survival and prognostic factors in pathologic stage adenocarcinoma by the new 20 09 TNM classification[J]. Tumor Biol, 2014, 35(6): 5905-10. [6] Fan X, Zhang X, Wang H, et al. Reevaluation of survival and prognostic factors in pathologic stage adenocarcinoma by the new 2009 TNM classification[J]. Tumor Biol, 2014, 35(6): 5905-10. doi: 10.1007/s13277-014-1781-8
[7] Shimokawa H, Uramoto H, Onitsuka T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence[J]. J Thorac Cardiovasc Surg, 2011, 14 1(4): 895-8. [7] Shimokawa H, Uramoto H, Onitsuka T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence[J]. J Thorac Cardiovasc Surg, 2011, 141(4): 895-8. doi: 10.1016/j.jtcvs.2010.09.044
[8] Park S, Choi YL, Sung CO, et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients[J]. Histol Histopathol, 2012, 27(2): 197-207. http://cn.bing.com/academic/profile?id=285988926&encoded=0&v=paper_preview&mkt=zh-cn
[8] Park S, Choi YL, Sung CO, et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients[J]. Histol Histopathol, 2012, 27(2): 197-207. [9] Kawamura M, Saigusa S, Toiyama Y, et al. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy[J]. Anticancer Res, 2012, 32(4): 1527-31. http://cn.bing.com/academic/profile?id=1934485925&encoded=0&v=paper_preview&mkt=zh-cn
[9] Kawamura M, Saigusa S, Toiyama Y, et al. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy[J]. Anticancer Res, 2012, 32(4): 1527-31. [10] Stein U, Walther W, Arh F, et al. MACC1, a newly identified key regulator of HGF－MET signaling, predicts colon cancer metastasis[J]. Nat Med, 2009, 15(1): 59-67. [10] Stein U, Walther W, Arh F, et al. MACC1, a newly identified key regulator of HGF－MET signaling, predicts colon cancer metastasis[J]. Nat Med, 2009, 15(1): 59-67. doi: 10.1038/nm.1889
[11] Arlt F, Stein U. Colon cancer metastasis:MACC1 and Met as metastasis pacemakers[J]. Int J Biochem Cell Biol, 2009, 41(12): 2356-9. doi: 10.1016/j.biocel.2009.08.001
[11] Arlt F, Stein U. Colon cancer metastasis:MACC1 and Met as metastasis pacemakers[J]. Int J Biochem Cell Biol, 2009, 41(12): 23 56-9. [12] Yang T, Kong B, Kuang YQ, et al. Overexpression of MACC1 protein and its clinical implications in patients with glioma[J]. Tumor Biol, 2014, 35(1): 815-9. [12] Yang T, Kong B, Kuang YQ, et al. Overexpression of MACC1 protein and its clinical implications in patients with glioma[J].Tumor Biol, 2014, 35(1): 815-9. doi: 10.1007/s13277-013-1112-5
[13] 姚继彬, 段耀星, 张永斌, 等. 胃癌组织MACC1表达及其临床意义分析[J]. 中华肿瘤防治杂志, 2013, 20(6): 444-7. http://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201306012.htm Yao JB, Duan YX, Zhang YB, et al. Expression and clinical implications of MACC1 in gastric cancer tissue[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2013, 20(6): 444-7. http://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201306012.htm
[13] Yao JB, Duan YX, Zhang YB, et al. Expression and clinical implications of MACC1 in gastric cancer tissue[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2013, 20(6): 444-7. [姚继彬, 段耀星, 张永斌, 等. 胃癌组织MACC1表达及其临床意义分析[J]. 中华 肿瘤防治杂志, 2013, 20(6): 444-7.] [14] 何彬, 吴长利, 胡海龙, 等. MACC1及c-Met在前列腺癌组织中的表达[J]. 天津医药, 2015, 43(2): 175-8. http://youxian.cnki.com.cn/yxdetail.aspx?filename=HNYY20160628000&dbname=CAPJ2015 He B, Wu CL, Hu HL, et al. Expressions of MACC1 and c-Met genes in prostate cancer tissues[J]. Tianjin Yi Yao, 2015, 43(2): 175-8. http://youxian.cnki.com.cn/yxdetail.aspx?filename=HNYY20160628000&dbname=CAPJ2015
[14] He B, Wu CL, Hu HL, et al. Expressions of MACC1 and c-Met genes in prostate cancer tissues[J]. Tianjin Yi Yao, 2015, 43(2): 17 5-8. [何彬, 吴长利, 胡海龙, 等. MACC1及c-Met在前列腺癌 组织中的表达[J]. 天津医药, 2015, 43(2): 175-8.] [15] Chundong G, Uramoto H, Onitsuka T, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis[J]. Anticancer Res, 2011, 31(4): 1141-5. http://cn.bing.com/academic/profile?id=2096886845&encoded=0&v=paper_preview&mkt=zh-cn
[15] Chundong G, Uramoto H, Onitsuka T, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis[J]. Anticancer Res, 2011, 31(4): 1141-5. [16] Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy[J]. Expert Opin Ther Targets, 2012, 16(6): 553-72. doi: 10.1517/14728222.2012.680957
[16] Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy[J]. Expert Opin Ther Targets, 2012, 16 (6): 553-72. [17] Corso S, Comoglio PM, Giordano S. Cancer therapy :can the challenge be MET[J]. Trends Mol Med, 2005, 11(6): 284-92. [17] Corso S, Comoglio PM, Giordano S. Cancer therapy :can the challenge be MET[J]. Trends Mol Med, 2005, 11(6): 284-92. doi: 10.1016/j.molmed.2005.04.005
[18] Sgambato A, Casaluce F, Maione P, et al. The c-Met inhibitors : a new class of drugs in the battle against advanced nonsmall-cell lung cancer[J]. Curr Pharm Des, 2012, 18(37): 6155-68. doi: 10.2174/138161212803582478
[18] Sgambato A, Casaluce F, Maione P, et al. The c-Met inhibitors : a new class of drugs in the battle against advanced nonsmall-cell lung cancer[J]. Curr Pharm Des, 2012, 18(37): 6155-68. [19] Lv H, Shan B, Tian Z, et al. Soluble c-Met is reliable and sensitive marker to detect c-Met expression level in lung cancer[J]. Biomed Res Int, 2015, 2015: 626578. [19] Lv H, Shan B, Tian Z, et al. Soluble c-Met is reliable and sensitive marker to detect c-Met expression level in lung cancer[J]. Biomed Res Int, 2015, 2015: 626578. http://cn.bing.com/academic/profile?id=2021706017&encoded=0&v=paper_preview&mkt=zh-cn
[20] Landi L, Minuti G, D’Incecco A, et al. Targeting c-MET in the battle against advanced non-small cell lung cancer[J]. Curr Opin Oncol, 2013, 25(2): 130-6. [20] Landi L, Minuti G, D’Incecco A, et al. Targeting c-MET in the battle against advanced non-small cell lung cancer[J]. Curr Opin Oncol, 2013, 25(2): 130-6. doi: 10.1097/CCO.0b013e32835daf37
[21] Boardman LA. Overexpression of MACC1 leads to downstream activation metastasis and recurrence of colorectal cancer[J].Genome Med, 2009, 1(4): 36. http://cn.bing.com/academic/profile?id=2154795881&encoded=0&v=paper_preview&mkt=zh-cn
[21] Boardman LA. Overexpression of MACC1 leads to downstream activation metastasis and recurrence of colorectal cancer[J]. Genome Med, 2009, 1(4): 36. [22] Huh CG, Factor VM, Sánchez A, et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair[J]. Proc Natl Acad Sci U S A, 2004, 101(13): 4477-82. doi: 10.1073/pnas.0306068101
[22] Huh CG, Factor VM, Sánchez A, et al. Hepatocyte growth factor/ c-met signaling pathway is required for efficient liver regeneration and repair[J]. Proc Natl Acad Sci U S A, 2004, 101(13): 4477-82.
计量
- 文章访问数: 1563
- HTML全文浏览量: 411
- PDF下载量: 439
